Antipsychotic use in older adults with Parkinson's disease
Identifieur interne : 000046 ( Istex/Curation ); précédent : 000045; suivant : 000047Antipsychotic use in older adults with Parkinson's disease
Auteurs : Connie Marras [Canada] ; Alexander Kopp [Canada] ; Feng Qiu [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada]Source :
- [ 0885-3185 ]
Abstract
The choice of agents to treat psychotic symptoms in Parkinson's disease is important given the potential for antipsychotics to worsen Parkinsonism. The purpose of this study was to estimate the incidence of psychotic symptoms requiring treatment in individuals with Parkinson's disease after starting dopaminergic medications, and to describe the agents being selected as initial antipsychotic therapy. Using the administrative health care databases of Ontario, Canada, individuals 66 years of age or older with Parkinson's disease who were newly treated with dopaminergic agents were identified. Subsequent prescriptions for antipsychotic medications were then identified. A total of 10,347 older adults were newly started on dopaminergic agents between 1998 and 2003. The Kaplan–Meier estimate for the cumulative probability of requiring an antipsychotic at 7 years was 35%; 499 individuals (4.8%; 5.2/100 person–years) were prescribed an antipsychotic within 1 year of starting dopaminergic therapy. The proportion of initial antipsychotic prescriptions for typical antipsychotics decreased from 56% (42 of 75) in 1998 to 9% (8 of 88) in 2002. Antipsychotic use is common in individuals with Parkinsonism newly treated with dopaminergic medication. Typical antipsychotics are still commonly being chosen as first‐line agents for older patients, indicating a need for interventions to improve practice. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21192
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000046
Links to Exploration step
ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6Le document en format XML
<record><TEI wicri:istexFullTextTei="no"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antipsychotic use in older adults with Parkinson's disease</title><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="1"><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Movement Disorders Centre, Toronto Western Hospital, 7 McL, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, 7 McL, 399 Bathurst Street, Toronto, ON M5T 2S8</wicri:regionArea></affiliation></author><author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Qiu, Feng" sort="Qiu, Feng" uniqKey="Qiu F" first="Feng" last="Qiu">Feng Qiu</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Kunin–Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Kunin–Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21192</idno><idno type="url">https://api-v5.istex.fr/document/0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000046</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000046</idno><idno type="wicri:Area/Istex/Curation">000046</idno></publicationStmt><sourceDesc><biblStruct><analytic><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="1"><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Movement Disorders Centre, Toronto Western Hospital, 7 McL, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, 7 McL, 399 Bathurst Street, Toronto, ON M5T 2S8</wicri:regionArea></affiliation></author><author><name sortKey="Kopp, Alexander" sort="Kopp, Alexander" uniqKey="Kopp A" first="Alexander" last="Kopp">Alexander Kopp</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Qiu, Feng" sort="Qiu, Feng" uniqKey="Qiu F" first="Feng" last="Qiu">Feng Qiu</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><mods:affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Sykora, Kathy" sort="Sykora, Kathy" uniqKey="Sykora K" first="Kathy" last="Sykora">Kathy Sykora</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Shulman, Kenneth I" sort="Shulman, Kenneth I" uniqKey="Shulman K" first="Kenneth I." last="Shulman">Kenneth I. Shulman</name><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Psychiatry, Sunnybrook and Women's College Health Sciences Centre, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name><affiliation wicri:level="1"><mods:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Medicine, University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Toronto, Toronto</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Kunin–Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Kunin–Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto</wicri:regionArea></affiliation></author></analytic><series><idno type="ISSN">0885-3185</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The choice of agents to treat psychotic symptoms in Parkinson's disease is important given the potential for antipsychotics to worsen Parkinsonism. The purpose of this study was to estimate the incidence of psychotic symptoms requiring treatment in individuals with Parkinson's disease after starting dopaminergic medications, and to describe the agents being selected as initial antipsychotic therapy. Using the administrative health care databases of Ontario, Canada, individuals 66 years of age or older with Parkinson's disease who were newly treated with dopaminergic agents were identified. Subsequent prescriptions for antipsychotic medications were then identified. A total of 10,347 older adults were newly started on dopaminergic agents between 1998 and 2003. The Kaplan–Meier estimate for the cumulative probability of requiring an antipsychotic at 7 years was 35%; 499 individuals (4.8%; 5.2/100 person–years) were prescribed an antipsychotic within 1 year of starting dopaminergic therapy. The proportion of initial antipsychotic prescriptions for typical antipsychotics decreased from 56% (42 of 75) in 1998 to 9% (8 of 88) in 2002. Antipsychotic use is common in individuals with Parkinsonism newly treated with dopaminergic medication. Typical antipsychotics are still commonly being chosen as first‐line agents for older patients, indicating a need for interventions to improve practice. © 2006 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000046 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000046 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:0C3F9C4EA52476687FAD7642CB4ED5E3CF6DD2D6
|texte= Antipsychotic use in older adults with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |